Search clinical trials for: Darapladib (SB480848)

Total 24 results

GlaxoSmithKline

Completed

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Atherosclerosis

United States
GlaxoSmithKline

Completed

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

Atherosclerosis

Japan
GlaxoSmithKline

Completed

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

Atherosclerosis

Japan
GlaxoSmithKline

Completed

A Study With Darapladib to Collect Tolerability Information

Atherosclerosis

United States
GlaxoSmithKline
The TIMI Study Group

Completed

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

Acute Coronary Syndrome

United States, France, Netherlands, Ukraine, Germany, Taiwan, Bulgaria, Hungary, Poland, Russian Federation, Argentina, Belgium, Peru, Philippines, Sweden, Thailand, Israel, Spain, Korea, Republic of, Australia, Czechia, Japan, New... and more
GlaxoSmithKline

Completed

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Atherosclerosis

United States
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline; National...

Completed

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Endothelial Dysfunction

United States
GlaxoSmithKline

Completed

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Retinopathy, Diabetic

Australia, Netherlands, Italy, Germany, Denmark
GlaxoSmithKline

Completed

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

Coronary Heart Disease
GlaxoSmithKline

Completed

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Atherosclerosis

United States
GlaxoSmithKline

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Atherosclerosis

United States
GlaxoSmithKline

Completed

Darapladib China PK

Atherosclerosis

China
GlaxoSmithKline

Completed

Integrated Biomarker And Imaging Study - 2

Atherosclerosis

Netherlands, Belgium, Germany, Czechia, France, Austria, Spain, Norway, Poland, Denmark, Switzerland
GlaxoSmithKline

Completed

A Study To Determine The Effect Of SB-480848 On Asthma

Atherosclerosis

United States, Germany
GlaxoSmithKline

Completed

SB-480848 In Subjects With Coronary Heart Disease

Atherosclerosis

United States, Germany, Estonia, Spain, Argentina, Canada, France, Netherlands, Australia, Bulgaria, Romania, Hungary, Denmark, India, New Zealand, Pakistan
GlaxoSmithKline

Completed

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

Atherosclerosis

United Kingdom
GlaxoSmithKline

Completed

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Atherosclerosis

United States
GlaxoSmithKline

Completed

Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy

Atherosclerosis
GlaxoSmithKline

Completed

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY)

Atherosclerosis

United States, Argentina, Australia, France, Germany, Netherlands, Taiwan, Bulgaria, Estonia, Poland, Russian Federation, Spain, Belgium, Canada, Peru, Philippines, Sweden, Thailand, Korea, Republic of, Hong Kong, Hungary, Slovakia, Ukrain... and more
GlaxoSmithKline

Completed

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Atherosclerosis

United States
Jun Li

Unknown

One Dose Versus Three Weekly Doses of Benzathine Penicillin G for Patients With Early Syphilis

Syphilis

China
GlaxoSmithKline

Completed

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Atherosclerosis

United States
GlaxoSmithKline

Completed

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

Atherosclerosis

United States
University of Nebraska
National Cancer Institute (NCI)

Withdrawn

Talabostat in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

Search clinical trials for: Darapladib (SB480848)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations